MGX (Metagenomi Therapeutics) Other Current Liabilities: $2.46 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.23
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Other Current Liabilities?

Metagenomi Therapeutics MGX 10 Other Current Liabilities is $2.46 Mil as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Metagenomi Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $2.46 Mil.

Metagenomi Therapeutics's quarterly other current liabilities declined from Sep. 2025 ($5.11 Mil) to Dec. 2025 ($4.99 Mil) and declined from Dec. 2025 ($4.99 Mil) to Mar. 2026 ($2.46 Mil).

Metagenomi Therapeutics's annual other current liabilities declined from Dec. 2023 ($7.26 Mil) to Dec. 2024 ($5.35 Mil) and declined from Dec. 2024 ($5.35 Mil) to Dec. 2025 ($4.99 Mil).

Metagenomi Therapeutics Other Current Liabilities Related Terms

Metagenomi Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Other Current Liabilities Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
2.24 4.82 7.26 5.35 4.99

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.41 4.06 5.11 4.99 2.46
MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $2.46 Mil mean?
Metagenomi Therapeutics (MGX) has a Other Current Liabilities of $2.46 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Metagenomi Therapeutics.
Is Metagenomi Therapeutics' Other Current Liabilities too high?
Metagenomi Therapeutics' current Other Current Liabilities is $2.46 Mil. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Other Current Liabilities compare to KALA and HYPD?
Metagenomi Therapeutics' Other Current Liabilities of $2.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Metagenomi Therapeutics. Metagenomi Therapeutics's current Other Current Liabilities is $2.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Other Current Liabilities of $2.46 Mil. The current Other Current Liabilities is $2.46 Mil. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Other Current Liabilities is $2.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.23
Price